Pennsylvania integrated health system Geisinger has entered into a multi-year partnership with a company called Tempus to use machine learning and artificial intelligence to build precision medicine tools for cardiology.
The goal of the effort is to enable the prediction of dangerous cardiac events and diseases before they occur, allowing for potentially life-saving intervention. Geisinger’s clinical data will be analyzed by Tempus’ proprietary machine learning technology. The Geisinger system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine.
The collaboration will reside within Geisinger as part of its Cardiac Imaging and Technology Laboratory, which is co-directed by Brandon Fornwalt, M.D., Ph.D., and Christopher Haggerty, Ph.D. Through strategic investment in machine learning, their team of engineers, researchers and physician scientists have been responsible for several projects that are already leveraging artificial intelligence and machine learning to positively impact patient care. By utilizing a clinical data structuring engine, Tempus is able to use its proprietary technology to analyze a combination of data points from various sources to track outcome and response data that can lead to more proactive cardiovascular treatments and interventions, the company said. Through this partnership with Geisinger, Tempus is expanding its scope beyond oncology to cardiovascular disease.
“Our mission is to improve the lives of patients with cardiovascular disease through the development and application of state-of-the-art technologies,” said Dr. Fornwalt, in a statement “Tempus is one of the best in the business at building and translating these kinds of technologies, so we are very excited to work with them. This collaboration brings together complementary areas of expertise unified behind a joint vision of integrating the best technology available to positively impact our patients.”
